Market cap
$8.5m
End-of-day close multiplied by current shares on issue.
Result releasedAnnolyse analysis published
Revenue reached $2.9m and cash rose to $0.534m, but operating cash outflow widened to $3.0m.
Revenue context before the current result.
Operating profit margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Market context
These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.
The latest close and share count context for the market price.
Market cap
$8.5m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.01
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
1.99x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY26 vs FY25
Revenue
$2.9m
+93.5% ↑ vs $1.5m
Net profit after tax
−$3.4m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Net cash inflow from operating activities
−$3m
-6.2% ↓ vs −$2.8m
Cash and cash equivalents
$0.53m
+121.6% ↑ vs $0.24m
Total assets
$7.2m
+5.8% ↑ vs $6.8m
Analysis ofRUA FY26Result releasedAnnolyse analysis published
What changed
The higher cash balance provides some buffer, but borrowings still increased alongside continuing operating losses.
Total revenue and other income rose 93.5% to $2.9m from $1.5m, while revenue from customers rose 71% to $2.58m on the company's own reporting — these are different revenue bases from the same release and should not be treated as interchangeable. The pre-tax loss narrowed 2.8% to $3.4m from $3.5m, but operating cash outflow widened to $3.0m from $2.8m over the same period.
Within the partial working-capital balance proxy, trade debtors rose 145.3% to $0.525m and inventories rose 45.2% to $0.588m. The comparable partial operating working-capital balance proxy increased by $0.5m to $1.1m from $0.6m. It is not a cash-flow movement.
What matters
With operating cash outflow of $3.0m, financial flexibility still depends on the terms and availability of the group's funding facilities. Total assets of $7.2m sit at the lower edge of Annolyse's historical range, against a three-period mean of $20.4m, reinforcing that the balance sheet has thinned materially rather than simply fluctuated within a normal band.
The loss narrowed on a statutory basis, but the cash outflow from operations widened by 6.2% to $3.0m, so the P&L improvement did not translate into a smaller cash burn — an earnings-quality gap that matters because it means the reported loss understates the cash pressure investors should track.
The higher trade debtors and inventories increased the partial operating working-capital balance proxy by $0.5m. Separately, the cash-flow statement shows $0.612m absorbed by working-capital movements, but the filing does not provide enough detail to determine how much of the period-end balance increase reflects timing, growth, or a change in operating mix.
Expectations
The half-year split shows $1.3m of statutory revenue in the first half against $1.6m implied in the second half (45.6% first-half share), indicating second-half weighting on a reported basis, though this should not be read as an underlying trading-momentum signal absent further disclosure.
Without a stated cash runway or funding target, investors cannot assess whether the current borrowing increase is a one-off bridge or the start of a recurring reliance on debt.
Quality of result
Net tangible assets per share of $0.01 point to a thin residual buffer, while the $0.534m cash balance remains small relative to the $3.0m annual operating cash outflow.
Revenue growth is real on both bases disclosed, but its durability depends on customer concentration and contract timing that are not detailed here; the UK export agreement cited in commentary is a named driver of future growth rather than a component already reconciled into FY26 revenue.
Unresolved
This briefing cannot assess the specific terms, maturity, or covenant conditions attached to the increased borrowings, or the precise financial detail behind the discontinued-operation overlay.
Chat
Ask follow-up questions about Rua Bioscience's FY26 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
FY26 Preliminary Financial Results
FY26 / financial reportFY26 Preliminary Financial Results Announcement
FY26 / results announcementRua Bioscience FY25 Annual Report
FY25 / financial reportRua Bioscience FY25 Annual Report Announcement
FY25 / results announcementHalf-Year Financial Results Announcement
HY26 / results announcementHalf-Year Financial Statements
HY26 / financial reportASM Presentation FY25
FY25 / commentaryASM Presentation FY25
HY26 / commentaryRelated insights
Compare this result's metrics with other covered NZX companies.
Earnings quality and statutory distortions
This result includes a statutory earnings-quality distortion flag.
Revenue growth context
Revenue growth was 93.5% for this reporting period.
Leverage and balance-sheet risk
Net debt / EBITDA is -0.39x, -0.13x versus the prior comparable period.
Working-capital pressure
Inventory days were 73 days, -24 days versus the prior comparable period.
Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.